Education
About Us
Working with TipRanks
Follow Us
Stoke Therapeutics Inc (STOK)
NASDAQ:STOK
STOK Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
STOK Stock 12 Month Forecast
Average Price Target
$29.75
▲(32.40% Upside)
| Highest Price Target$39.00 | Average Price Target$29.75 | Lowest Price Target$22.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$35
Buy
55.76%
Upside
Reiterated
11/05/25
Buy Rating for Stoke Therapeutics: Promising Potential of Zorevunersen in Dravet Syndrome TreatmentValuation and Risks. Our price target of $35 is based on an equally weighted composite of: (a) $46 per share, as a 25x multiple of taxed and diluted 2034 EPS of $6 per share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $25 per share with a discount rate of 14% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental- stage biopharmaceutical company.
Needham
$35
Buy
55.76%
Upside
Reiterated
11/05/25
Canaccord Genuity
$24→$28
Buy
24.61%
Upside
Reiterated
11/05/25
TD Cowen
―
Buy
―
Reiterated
11/04/25
Promising Potential and Strong Financial Position Drive Buy Rating for Stoke Therapeutics3:27 AM Stoke Therapeutics (NASDAQ: STOK) Buy (1) ESG Target: NA EMPEROR Ph3 Progressing Well – On BTD View Full Report THE TD COWEN INSIGHT Ph3 EMPEROR trial enrolling well; expect enrollment completion in H2:26, data in H2:27. Potential for expedited approval based on FDA meeting in Dec '25; briefing book submitted with 4 yrs of data showing profound/durable efficacy on seizures & Vineland + clean safety. Ph1 study of STK-002 (OPA1 ASO) now recruiting. Cash runway to mid-'28 funds Dravet & ADOA. We like the risk-reward. Maintain Buy.
BTIG
$39
Buy
73.56%
Upside
Reiterated
11/04/25
Stoke Therapeutics: Promising Outlook with Breakthrough Therapy Designation and Strong Financial PositionWe expect this estimate is conservative as it's hard to imagine most Dravet families don't know about the Stoke efforts. The major reason for screen failure was discussed on the call as hitting a minimum number of seizures prior to enrollment. This hurdle is again a positive as seizure reductions (the primary endpoint) should be greater in a shorter time for an active drug. We see the case for early action as compelling, although there are also benefits to launching after a full-blown and highly successful P3 trial. We see the major evidence driving early approval to be the unique ability of zorevunersen to generate beyond-seizure effects - the readouts that most clearly demonstrate disease correction.
J.P. Morgan
$15→$25
Hold
11.26%
Upside
Reiterated
11/03/25
Leerink Partners
$18→$30
Buy
33.51%
Upside
Reiterated
10/07/25
Chardan Capital
$24
Buy
6.81%
Upside
Reiterated
08/13/25
Wedbush
$22
Buy
-2.09%
Downside
Reiterated
08/13/25
Jefferies
$30
Buy
33.51%
Upside
Initiated
07/18/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$35
Buy
55.76%
Upside
Reiterated
11/05/25
Buy Rating for Stoke Therapeutics: Promising Potential of Zorevunersen in Dravet Syndrome TreatmentValuation and Risks. Our price target of $35 is based on an equally weighted composite of: (a) $46 per share, as a 25x multiple of taxed and diluted 2034 EPS of $6 per share discounted back to and (b) an NPV discounted cash flow between 2025-2034 of $25 per share with a discount rate of 14% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of an early developmental- stage biopharmaceutical company.
Needham
$35
Buy
55.76%
Upside
Reiterated
11/05/25
Canaccord Genuity
$24→$28
Buy
24.61%
Upside
Reiterated
11/05/25
TD Cowen
―
Buy
―
Reiterated
11/04/25
Promising Potential and Strong Financial Position Drive Buy Rating for Stoke Therapeutics3:27 AM Stoke Therapeutics (NASDAQ: STOK) Buy (1) ESG Target: NA EMPEROR Ph3 Progressing Well – On BTD View Full Report THE TD COWEN INSIGHT Ph3 EMPEROR trial enrolling well; expect enrollment completion in H2:26, data in H2:27. Potential for expedited approval based on FDA meeting in Dec '25; briefing book submitted with 4 yrs of data showing profound/durable efficacy on seizures & Vineland + clean safety. Ph1 study of STK-002 (OPA1 ASO) now recruiting. Cash runway to mid-'28 funds Dravet & ADOA. We like the risk-reward. Maintain Buy.
BTIG
$39
Buy
73.56%
Upside
Reiterated
11/04/25
Stoke Therapeutics: Promising Outlook with Breakthrough Therapy Designation and Strong Financial PositionWe expect this estimate is conservative as it's hard to imagine most Dravet families don't know about the Stoke efforts. The major reason for screen failure was discussed on the call as hitting a minimum number of seizures prior to enrollment. This hurdle is again a positive as seizure reductions (the primary endpoint) should be greater in a shorter time for an active drug. We see the case for early action as compelling, although there are also benefits to launching after a full-blown and highly successful P3 trial. We see the major evidence driving early approval to be the unique ability of zorevunersen to generate beyond-seizure effects - the readouts that most clearly demonstrate disease correction.
J.P. Morgan
$15→$25
Hold
11.26%
Upside
Reiterated
11/03/25
Leerink Partners
$18→$30
Buy
33.51%
Upside
Reiterated
10/07/25
Chardan Capital
$24
Buy
6.81%
Upside
Reiterated
08/13/25
Wedbush
$22
Buy
-2.09%
Downside
Reiterated
08/13/25
Jefferies
$30
Buy
33.51%
Upside
Initiated
07/18/25
Best Analysts Covering Stoke Therapeutics
1 Month
xxx
Success Rate
20/36 ratings generated profit
Average Return
+1.32%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +1.32% per trade.
3 Months
xxx
Success Rate
8/14 ratings generated profit
Average Return
+9.76%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +9.76% per trade.
1 Year
Success Rate
16/24 ratings generated profit
Average Return
+61.66%
reiterated a buy rating 5 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +61.66% per trade.
2 Years
xxx
Success Rate
13/14 ratings generated profit
Average Return
+130.87%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +130.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
STOK Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Oct 25
Nov 25
Strong Buy
6
9
6
6
5
Buy
3
7
12
16
14
Hold
5
5
2
1
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
21
20
23
23
Each month's total comprises the sum of three months' worth of ratings.
STOK Financial Forecast
STOK Stock Forecast FAQ
What is STOK’s average 12-month price target, according to analysts?
Based on analyst ratings, Stoke Therapeutics Inc’s 12-month average price target is 29.75.
What is STOK’s upside potential, based on the analysts’ average price target?
Stoke Therapeutics Inc has 32.40% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is STOK a Buy, Sell or Hold?
Stoke Therapeutics Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is Stoke Therapeutics Inc’s price target?
The average price target for Stoke Therapeutics Inc is 29.75. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $39.00 ,the lowest forecast is $22.00. The average price target represents 32.40% Increase from the current price of $22.47.
The highest analyst price target is $39.00 ,the lowest forecast is $22.00. The average price target represents 32.40% Increase from the current price of $22.47.
What do analysts say about Stoke Therapeutics Inc?
Stoke Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of STOK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.